• CBT-502 is a novel IgG4 humanized monoclonal antibody against the Programmable Death Ligand-1 (PDL-1) membrane receptor on tumor cells with world-wide rights granted to CBT Pharmaceuticals, Inc. and China rights granted to Chia Tai TianQing (CTTQ).
  • CBT-502 is undergoing IND supporting studies toward the filing of an Investigational Drug Application in China by our partner CTTQ.